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Abstract
Background: Genome-wide association studies (GWAS) have identified multiple genetic loci for C-reactive protein
(CRP) and lipids, of which some overlap. We aimed to identify genetic pleiotropy among CRP and lipids in order to
better understand the shared biology of chronic inflammation and lipid metabolism.
Results: In a bivariate GWAS, we combined summary statistics of published GWAS on CRP (n = 66,185) and lipids,
including LDL-cholesterol, HDL-cholesterol, triglycerides, and total cholesterol (n = 100,184), using an empirical
weighted linear-combined test statistic. We sought replication for novel CRP associations in an independent sample
of 17,743 genotyped individuals, and performed in silico replication of novel lipid variants in 93,982 individuals. Fifty
potentially pleiotropic SNPs were identified among CRP and lipids: 21 for LDL-cholesterol and CRP, 20 for
HDL-cholesterol and CRP, 21 for triglycerides, and CRP and 20 for total cholesterol and CRP. We identified and
significantly replicated three novel SNPs for CRP in or near CTSB/FDFT1 (rs10435719, Preplication: 2.6 × 10
−5),
STAG1/PCCB (rs7621025, Preplication: 1.4 × 10
−3) and FTO (rs1558902, Preplication: 2.7 × 10
−5). Seven pleiotropic lipid loci
were replicated in the independent set of MetaboChip samples of the Global Lipids Genetics Consortium.
Annotating the effect of replicated CRP SNPs to the expression of nearby genes, we observed an effect of
rs10435719 on gene expression of FDFT1, and an effect of rs7621025 on PCCB.
Conclusions: Our large scale combined GWAS analysis identified numerous pleiotropic loci for CRP and lipids
providing further insight in the genetic interrelation between lipids and inflammation. In addition, we provide
evidence for FDFT1, PCCB and FTO to be associated with CRP levels.
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Background
Genome-wide association studies (GWAS) have identi-
fied hundreds of genetic loci for cardiovascular disease
and it’s risk factors, including chronic inflammation and
lipids [1–3]. Some of the identified genetic variants are as-
sociated with more than one phenotype, termed genetic
pleiotropy [4]. Examples are APOC1(rs4420638) and
HNF1A (rs1183910), which are associated both with lipids
and C-reactive protein (CRP) [2, 3]. As randomized
clinical trials have shown a coextending effect of statin
treatment on the lowering of LDL-cholesterol and CRP,
we do expect inflammation and lipids to share certain bio-
logical pathways [5, 6]. Moreover, there is accumulating
evidence that the pleiotropic effects are partially inde-
pendent, although the biological mechanisms are not fully
understood [7]. The identification of further pleiotropic
genes could provide insight into the biological mecha-
nisms that link chronic inflammation to lipids.
Therefore, we aimed to identify further shared genes
for lipids and CRP. In order to enhance the statistical
power of genetic studies to find pleiotropic genes for the
correlated phenotypes of interest, we applied a method
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that combines GWAS meta-analysis summary statistics
allowing for mixed directions of effect, a common ob-
served phenomenon in genetic pleitropy [8]. In a second
step we sought to replicate novel associations with lipids
and CRP in an independent sample of 93,982 genotyped
individuals for lipids and 17,743 genotyped individuals
for CRP. We identified multiple overlapping genetic var-
iants between CRP and lipids and confirmed novel genes
implicated in the biology of chronic inflammation.
Results
Bivariate genome-wide association analysis
We performed bivariate GWAS meta-analyses by com-
bining summary statistics (Z test statistics) from the uni-
variate GWAS of CRP pairing with the summary
statistics of each GWAS of the lipid phenotypes, using
an empirical-weighted linear-combined test statistics
(eLC) [8]. This method allows mixed genetic effects in
the univariate phenotype GWAS, a phenomenon com-
monly observed in genetic studies.
CRP and LDL-cholesterol
Manhattan plots for the bivariate GWAS are depicted in
Fig. 1. Table 1 indicates the results from the bivariate
analysis combining CRP and LDL-cholesterol genetic as-
sociation data. The bivariate analysis resulted in 21 po-
tentially pleiotropic loci. We identified fourteen loci
associated with CRP levels which had no genome-wide
significant SNP in the original GWAS of CRP. These po-
tential novel associations were located in or near
CELSR2, IRF2BP2, ABCG8, GCNT4, HLA-DQB1, FRK,
TRIB1, FADS2, ST3GAL4, BRAP, C12orf51, CARM1/
LDLR, NCAN and RASIP1. The potential novel associa-
tions for LDL-cholesterol were located in or near GCKR,
IL1F10, RORA, RASIP1 and in HNF4A. The SNPs identi-
fied in the bivariate GWAS near HLA-DQB1, FRK,
BRAP, c12orf51 and CARM1/LDLR were not genome-
wide significant in the original univariate GWAS on
LDL-cholesterol, however other SNPs in their vicinity
were significant in the original GWAS on LDL-
cholesterol and the loci have thus been reported previ-
ously. The variants in and near PPP1R3B, HNF1A and
APOC1 were already genome-wide significant in both
GWAS of CRP and LDL-cholesterol.
CRP and HDL-cholesterol
We identified 20 potential pleiotropic SNPs (Table 2).
The variants near CELSR2, STAG1, HLA-DRA, JMJD1C,
FADS1, LIPC, CETP, LYPLA3, LIPG and MC4R were not
genome-wide significant in the original CRP meta-
GWAS analysis. Seven SNPs were potentially novel for both
CRP and HDL-cholesterol: the SNP rs12742376 located in
C1orf172 on chromosome 1 (Pbivariate = 1.4 × 10
−8), rs7621025
in STAG1 on chromosome 3 (Pbivariate= 1.2 × 10
−9), rs937
8212 near HLA-DRA (Pbivariate= 6.7 × 10
−10), rs10761731 in
JMJD1C (Pbivariate= 2.2 × 10
−8), rs1936797 in RSPO3 on
chromosome 6 (Pbivariate = 6.7 × 10
−9), rs4871137 near SNTB1
(Pbivariate = 3.3 × 10
−8) on chromosome 8 and the FTO SNP
rs1558902 (Pbivariate = 5.0 × 10
−9) on chromosome 16. The
variants near CELSR2 and PLTP were not significant in
the original GWAS on HDL-cholesterol, but these loci
were identified in the original GWAS. The variants in or
Fig. 1 Manhattan Plots of the Bivariate Genome-Wide Association Studies Combining C-Reactive Protein with LDL-Cholesterol, HDL-Cholesterol,
Triglycerides and Total Cholesterol
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near PABPC4, BAZ1B, PPP1R3B, APOC1 and HNF4A
were already genome-wide significant in both the CRP
and HDL-cholesterol univariate GWAS.
CRP and Triglycerides
Table 3 lists the 21 potentially pleiotropic SNPs that
were identified combining the GWAS results of triglyc-
erides and CRP. For triglycerides, we identified eleven
potential novel associations compared to the original
GWAS located in or near PABPC4, LEPR, ADAR, CRP,
IL1F10, PPP1R3B, CTSB/FDFT1, ARNTL, CABP1,
MC4R and HPN. The variant near PLA2G6 was not
genome-wide significant in the original GWAS, but this
locus was identified in the original GWAS. The variants
in and near ADAR, MSL2L1, HLA-C, CTSB/FDFT1,
LPL, ARNTL, FADS1, CETP, MC4R, SF4, HPN, ZNF335/
PLTP and PLA2G6 were potential novel associations
with CRP level. Five loci were not genome-wide signifi-
cant in either the original GWAS on CRP or triglycer-
ides: the SNP rs1127311 within ADAR on chromosome 1
(Pbivariate = 6.4 × 10
−9), rs10435719 located 77Kb upstream
of CTSB on chromosome 8 (Pbivariate = 2.0 × 10
−10),
rs10832027 located in the second intron of ARNTL
on chromosome 11 (Pbivariate = 9.4 × 10
−9), rs571312
on chromosome 18 near MC4R (Pbivariate = 2.8 × 10
−8),
and the chromosome 19 rs1688043 in the fifth intron
of HPN (Pbivariate = 4.1 × 10
−8). In both the original
GWAS of CRP and triglycerides, GCKR and APOC1
were already genome-wide significant.
CRP and total cholesterol
Twenty potentially pleiotropic SNPs were identified
combining CRP and total cholesterol (Table 4). The
SNPs in or near ZNF644, SLC44A4, C7orf50 and RORA
were potentially novel for total cholesterol. The variants
near HLX, ABCG5, IL1F10, C7orf60 and CARM1 were
not genome-wide significant in the GWAS on total chol-
esterol, but the loci were identified in this original
GWAS. For CRP, ZNF664, CELSR2, HLX, IRF2BP2,
ABCG5, GCNT4, SLC44A4, HLA-DQB1, FRK, ST3GAL4,
CARM1 and NCAN were potentially novel compared to
the univariate GWAS. The SNPs near ZNF644 and
Table 1 Results of Bivariate GWAS for C-Reactive Protein and LDL-Cholesterol Levels
SNP Chromosome Position Effect
Allele
C-reactive protein LDL-cholesterol Pleiotropy
significance
Gene
Beta P-value Beta P-value
rs646776 1 109620053 T −0.018 0.02 0.171 4.5 × 10−169 4.3 × 10−170 CELSR2
rs661955 1 232909479 C −0.021 1.7 × 10−3 0.034 1.2 × 10−10 3.2 × 10−12 IRF2BP2
rs3817588 2 27584716 T 0.053 1.8 × 10−10 0.024 4.2 × 10−4 6.4 × 10−12 GCKR
rs11887534 2 43919751 C −0.049 2.5 × 10−4 −0.134 1.1 × 10−31 9.0 × 10−33 ABCG8
rs12711751 2 113554236 T −0.044 1.6 × 10−10 0.014 4.8 × 10−3 1.2 × 10−11 IL1F10
rs4703642 5 74297918 A 0.018 3.0 × 10−3 −0.031 3.1 × 10−10 1.5 × 10−11 GCNT4
rs9275292 6 32771267 A 0.022 3.6 × 10−4 0.023 1.1 × 10−5 3.3 × 10−8 HLA-DQB1
rs3822857 6 116420624 C −0.032 2.7 × 10−6 −0.030 2.3 × 10−7 7.6 × 10−12 FRK
rs9987289 8 9220768 A −0.079 2.1 × 10−12 −0.071 2.0 × 10−14 2.3 × 10−24 PPP1R3B
rs8180991 8 126569532 C −0.026 9.0 × 10−4 −0.041 8.0 × 10−10 5.1 × 10−11 TRIB1
rs174574 11 61356918 A −0.027 1.7 × 10−3 −0.050 1.1 × 10−8 7.8 × 10−10 FADS2
rs11220463 11 125753421 A 0.032 2.8 × 10−3 −0.070 1.3 × 10−15 5.8 × 10−17 ST3GAL4
rs10744775 12 110580598 T 0.021 4.0 × 10−3 −0.030 5.3 × 10−7 3.1 × 10−8 BRAP
rs2285810 12 111183923 T 0.019 6.8 × 10−3 −0.030 8.3 × 10−8 8.3 × 10−9 C12orf51
rs1183910 12 119905190 A −0.151 4.6 × 10−113 0.042 5.8 × 10−15 5.6 × 10−128 HNF1A
rs340005 15 58665322 A 0.044 3.2 × 10−11 −0.015 3.4 × 10−3 1.7 × 10−12 RORA
rs1529711 19 10884434 T 0.030 8.4 × 10−4 0.037 1.5 × 10−6 1.5 × 10−8 CARM1/LDLR
rs2228603 19 19190924 T 0.036 2.9 × 10−3 −0.089 1.4 × 10−19 6.5 × 10−21 NCAN
rs4420638 19 50114786 A 0.240 1.0 × 10−129 −0.215 8.7 × 10−147 1.2 × 10−283 APOC1
rs2287921 19 53920084 T −0.019 3.6 × 10−3 −0.026 3.4 × 10−7 2.8 × 10−8 RASIP1
rs1800961 20 42475778 T −0.120 2.4 × 10−11 −0.070 2.4 × 10−5 3.8 × 10−14 HNF4A
Abbreviations: SNP single nucleotide polymorphism
For both CRP and the lipid phenotype, the effect estimates are according to the original GWAS
Chromosome and position are in NCBI genome build 36
Beta coefficient for CRP represents 1-unit change in the natural log–transformed CRP (mg/L) per copy increment in the coded allele
Beta coefficient for LDL-cholesterol represents 1-unit change in the standardized LDL-cholesterol levels per copy increment in the coded allele
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C7orf50 were novel pleiotropic loci for both CRP and
total cholesterol.
Replication of the novel pleiotropic loci
In total, we sought replication for 36 potential novel
SNPs for CRP in 17,743 genotyped individuals from
three independent cohort studies. Using a Bonferroni
corrected threshold for multiple testing (0.05/36 = 1.4 ×
10−3), three SNPs remained significantly associated with
CRP levels when we performed replication analysis
(Additional file 1: Table S1). These variants included the
SNPs rs10435719 in CTSB/FDFT1 (Preplication = 2.6 × 10
−5),
rs1558902 near FTO (Preplication = 2.7 × 10
−5) and rs7621025
near STAG1 (Preplication = 1.4 × 10
−3).
We aimed replication for 23 potential novel SNPs for
lipids (4 for LDL-cholesterol, 7 for HDL-cholesterol, 9
for triglycerides and 3 for total cholesterol) in an in silico
analysis including 93,982 individuals. We could signifi-
cantly replicate 2 variants for LDL-cholesterol
(HNF4A and RASIP1), three for HDL-cholesterol
(C1orf172, RSPO3 and STAG1), one for triglycerides
(CTSB) and one for total cholesterol (C7orf50)
(Additional file 1: Table S2).
Expression Quantitative Trait Loci (eQTL)
To annotate the effect of the replicated pleiotropic vari-
ants to the expression level of nearby genes, we investi-
gated the association between the pleiotropic variants
and gene expression levels in three different tissues rele-
vant to CRP and lipids by use of large publicly available
datasets: whole blood (N = 5311) [9], liver (N = 427 [10]
and 266 [11]) and adipose tissue [12] (N = 111). For the
replicated pleiotropic variant rs10435719 near CTSB and
FDFT1, we observed significant associations in whole
blood with expression levels of two genes: CTSB itself
(P = 1.67 × 10−6), and FDFT1 (P = 1.10 × 10−96). In
addition, the SNP rs7621025 near STAG1 and PCCB
was strongly associated with expression of the gene
PCCB in whole blood (P = 1.1 × 10−40). No eQTL effect
was observed in the liver and adipose tissue.
Discussion
We identified fifty potential pleiotropic SNPs which
affect both CRP and lipid levels, of which we replicated
three novel CRP variants: rs10435719 (CTSB/FDFT1),
rs7621025 (STAG1/PCCB) and rs1558902 (FTO). In
silico expression analyses suggested a role for
Table 2 Results of Bivariate GWAS Analyses for C-Reactive Protein and HDL-Cholesterol Levels
SNP Chromosome Position Effect
Allele
C-reactive protein HDL-cholesterol Pleiotropy
significance
Gene
Beta P-value Beta P-value
rs12742376 1 27157782 T −0.027 1.7 × 10−2 −0.046 2.8 × 10−7 1.4 × 10−8 C1orf172
rs4660293 1 39800767 A −0.044 1.2 × 10−9 0.034 4.0 × 10−10 3.1 × 10−15 PABPC4
rs646776 1 109620053 T −0.018 1.8 × 10−2 −0.033 6.4 × 10−8 3.2 × 10−9 CELSR2
rs7621025 3 137754936 T 0.028 1.7 × 10−4 0.026 4.1 × 10−6 1.2 × 10−9 STAG1
rs9378212 6 32553669 T 0.027 4.9 × 10−5 0.021 8.1 × 10−6 6.7 × 10−10 HLA-DRA
rs1936797 6 127474350 A 0.022 2.8 × 10−3 0.022 9.9 × 10−7 6.7 × 10−9 RSPO3
rs13244268 7 72549779 T 0.054 2.6 × 10−8 −0.045 1.3 × 10−9 1.2 × 10−13 BAZ1B
rs9987289 8 9220768 A −0.079 2.1 × 10−12 −0.083 6.4 × 10−25 1.2 × 10−39 PPP1R3B
rs4871137 8 121937732 T −0.021 2.2 × 10−3 −0.026 5.6 × 10−6 3.3 × 10−8 SNTB1
rs10761731 10 64697616 A 0.023 2.7 × 10−4 −0.025 2.5 × 10−7 2.2 × 10−8 JMJD1C
rs174546 11 61326406 T −0.017 1.2 × 10−2 −0.048 2.6 × 10−22 1.6 × 10−24 FADS1
rs1077834 15 56510771 T −0.016 4.0 × 10−2 −0.114 9.6 × 10−84 2.5 × 10−87 LIPC
rs1558902 16 52361075 A 0.032 2.0 × 10−6 −0.021 4.6 × 10−6 5.0 × 10−9 FTO
rs711752 16 55553712 A 0.016 1.8 × 10−2 0.192 2.1 × 10−297 4.3 × 10−308 CETP
rs17688076 16 66843928 A 0.019 4.9 × 10−2 0.070 3.9 × 10−22 1.8 × 10−23 LYPLA3
rs11874381 18 45457406 A 0.013 4.9 × 10−2 0.038 1.2 × 10−14 1.0 × 10−15 LIPG
rs12967135 18 56000003 A 0.029 1.2 × 10−4 −0.036 6.6 × 10−9 4.3 × 10−10 MC4R
rs4420638 19 50114786 A 0.240 1.0 × 10−129 0.071 4.4 × 10−21 2 × 10−164 APOC1
rs1800961 20 42475778 T −0.120 2.4 × 10−11 −0.129 1.1 × 10−15 3.9 × 10−28 HNF4A
rs6065906 20 43987422 T 0.036 5.9 × 10−6 0.058 1.9 × 10−22 5.1 × 10−29 PLTP
Abbreviations: SNP single nucleotide polymorphism
For both CRP and the lipid phenotype, the effect estimates are according to the original GWAS
Chromosome and position are in NCBI genome build 36
β coefficient for CRP represents 1-unit change in the natural log–transformed CRP (mg/L) per copy increment in the coded allele
Beta coefficient for HDL-cholesterol represents 1-unit change in the standardized HDL-cholesterol levels per copy increment in the coded allele
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rs10435719 in the gene expression of both CTSB and
FDFT1 and rs7621025 appeared to have an effect on the
gene expression of PCCB.
The locus harboring rs10435719 near CTSB and
FDFT1 that was identified for CRP in our study has pre-
viously been identified for triglycerides in the joint ana-
lysis of the Global Lipids Genetics Consortium
combining GWAS data with Metabochip association
results [13]. We observed a significant effect of
rs10435719 on the expression of both CTSB and FDFT1.
The effect of the CRP increasing allele (T) was weakly
associated with a decrease in the expression of CTSB,
whilst we observed a strong association of the T-allele
with an increase of FDFT1 gene expression. FDFT1 en-
codes the enzyme squalene synthase which is involved in
the cholesterol biosynthesis [14]. Apart from lipids,
FDFT1 has been identified in a GWAS on fatty liver dis-
ease [15]. Squalene Synthase Inhibitors (SSI) have been
developed and are successful in the reduction of choles-
terol levels as well as CRP levels [16]. This pleiotropic
effect of cholesterol synthesis blockers on both lipid
levels and inflammation is thought to be the conse-
quence of altered isoprenoids levels that may activate
pro-inflammatory pathways [17]. The observation that
the CRP increasing allele is associated with an increase
in FDFT1 gene expression suggests an effect of
rs10435719 on serum CRP through FDFT1. However,
we searched in large databases to identify robust eQTL
effects of the novel variants. Therefore, we were unable
to test the association between the expression and CRP
and we cannot draw a firm conclusion on the causal ef-
fect of the gene expression in the association between
the genetic variant and CRP.
We identified the SNP rs7621025 (STAG1/PCCB) as a
pleiotropic variant for HDL-cholesterol and CRP. We
confirmed the effect of rs7621025 on serum CRP in an
independent set of individuals and this genomic region
has been identified in a GWAS of lipids [13]. The SNP
rs7621025 is located within STAG1, but has a strong ef-
fect on the expression of PCCB, located ±300 kb down-
stream of rs7621025 on chromosome 3. PCCB has been
identified in a GWAS of the protein fibrinogen, an acute
Table 3 Results of Bivariate GWAS Analyses for C-Reactive Protein and Triglycerides Levels
SNP Chromosome Position Effect
Allele
C-reactive protein Triglycerides Pleiotropy
significance
Gene
Beta P-value Beta P-value
rs4660808 1 39791096 T 0.046 8.6 × 10−10 0.028 3.1 × 10−7 2.2 × 10−13 PABPC4
rs11208722 1 65943589 A −0.083 1.2 × 10−32 0.012 0.02 8.1 × 10−36 LEPR
rs1127311 1 152823287 A −0.031 9.3 × 10−7 0.012 5.5 × 10−3 6.4 × 10−9 ADAR
rs12755606 1 157936960 C −0.153 3.0 × 10−112 0.012 0.01 4.0 × 10−120 CRP
rs1260326 2 27584444 T 0.089 1.7 × 10−42 0.116 5.7 × 10−133 4.4 × 10−151 GCKR
rs13409360 2 113554573 A 0.048 1.3 × 10−12 −0.013 8.6 × 10−3 5.3 × 10−15 IL1F10
rs645040 3 137409312 T −0.023 2.5 × 10−3 0.030 2.5 × 10−8 4.6 × 10−11 MSL2L1
rs2524163 6 31367558 T 0.025 1.5 × 10−4 0.027 1.7 × 10−8 7.9 × 10−10 HLA-C
rs9987289 8 9220768 A −0.079 2.1 × 10−12 0.020 0.02 2.9 × 10−14 PPP1R3B
rs10435719 8 11814313 T 0.026 7.6 × 10−5 −0.022 4.1 × 10−6 2.0 × 10−10 CTSB
rs1441759 8 19909843 C 0.11 3.3 × 10−4 0.125 2.1 × 10−8 2.0 × 10−9 LPL
rs10832027 11 13313759 A 0.032 8.5 × 10−7 0.020 1.1 × 10−4 9.4 × 10−9 ARNTL
rs174546 11 61326406 T −0.017 0.01 0.048 5.4 × 10−24 5.2 × 10−27 FADS1
rs2686555 12 119579555 A −0.059 1.7 × 10−19 0.010 0.03 1.6 × 10−21 CABP1
rs11508026 16 55556829 T 0.014 0.03 −0.038 1.3 × 10−12 3.1 × 10−14 CETP
rs571312 18 55990749 A 0.033 3.5 × 10−5 0.026 1.2 × 10−5 2.8 × 10−8 MC4R
rs10401969 19 19268718 T −0.031 0.02 0.112 1.6 × 10−29 1.6 × 10−32 SF4
rs1688043 19 40245181 T −0.038 2.4 × 10−3 0.037 1.2 × 10−5 4.1 × 10−8 HPN
rs4420638 19 50114786 A 0.24 1.0 × 10−129 −0.068 5.4 × 10−22 1.7 × 10−171 APOC1
rs4465830 20 44018827 A 0.036 7.0 × 10−6 −0.050 2.0 × 10−17 2.0 × 10−24 ZNF335/PLTP
rs2277844 22 36907461 A −0.018 5.7 × 10−3 0.025 1.5 × 10−7 9.2 × 10−10 PLA2G6
Abbreviations: SNP single nucleotide polymorphism
For both CRP and the lipid phenotype, the effect estimates are according to the original GWAS
Chromosome and position are in NCBI genome build 36
β coefficient for CRP represents 1-unit change in the natural log–transformed CRP (mg/L) per copy increment in the coded allele
Beta coefficient for triglycerides represents 1-unit change in the standardized triglyceride levels per copy increment in the coded allele
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phase response protein sharing many genes with CRP
[18]. Our results provide further evidence that the PCCB
gene is involved in inflammation.
We identified the FTO gene as a pleiotropic locus for
CRP and HDL-cholesterol. The A allele of rs1558902
was associated with an increase of CRP and a decrease
in HDL cholesterol. In several GWAS on BMI, the A al-
lele of rs1558902 was also associated with an increase in
BMI [19, 20]. Previous studies have highlighted the
causal effect of obesity on inflammation [21], and the ef-
fect directions are consistent with mediation of both the
association with CRP and HDL-cholesterol by BMI. We
have previously shown that the effect of FTO on CRP is
indeed mediated through BMI [22]. Further research is
needed to demonstrate whether this is also true for
HDL-cholesterol. Our results provide further evidence
for the role of obesity in inflammation and highlight the
pleiotropic effects of the FTO locus on both chronic in-
flammation and lipid metabolism.
Genetic pleiotropy can be divided in biological and
mediated pleiotropy [4]. In biological pleiotropy, the ef-
fect of the pleiotropic variant on two or more ph-
enotypes is independent. In mediated pleiotropy, one
phenotype mediates the association between the genetic
variant and the second phenotype. Both biological and
mediated pleiotropic effects may occur for CRP and
lipids [23]. In the current study, we did not disentangle
the different subtypes of pleiotropy. Moreover, we ob-
served pleiotropic variants with an opposite direction of
effect than expected based on the phenotypical correl-
ation in observational epidemiological studies. In bio-
logical pleiotropy, opposite directions of effect may
occur. As an example, although CRP and LDL-
cholesterol are positively associated in observational epi-
demiological studies, the A-allele of the SNP rs1183910
(HNF1A) is associated with lower CRP levels but higher
LDL-cholesterol. Opposite direction of effects are often
seen in genetic studies and highlight the complex inter-
play between correlated phenotypes, in our study CRP
and lipids [20]. We did not disentangle the different sub-
types of pleiotropy, which is a limitation of the current
study.
Our study has certain strengths. We add to previous
studies showing that the multivariate method we applied
can be effectively utilized to identify potential novel and
pleiotropic loci. This method only requires GWAS
Table 4 Results of Bivariate GWAS Analyses for C-Reactive Protein and Total Cholesterol Levels
SNP Chromosome Position Effect
Allele
C-reactive protein Total cholesterol Pleiotropy
significance
Gene
Beta P-value Beta P-value
rs469772 1 91302893 T −0.042 1.6 × 10−7 −0.020 1.5 × 10−3 1.5 × 10−8 ZNF644
rs629301 1 109619829 T −0.017 2.8 × 10−2 0.149 5.8 × 10−131 5.7 × 10−132 CELSR2
rs17597773 1 219121384 C 0.020 7.5 × 10−3 −0.031 7.1 × 10−8 6.6 × 10−9 HLX
rs661955 1 232909479 C −0.021 1.7 × 10−3 0.036 1.0 × 10−12 2.2 × 10−14 IRF2BP2
rs1260326 2 27584444 T 0.089 1.7 × 10−42 0.055 7.3 × 10−27 2.6 × 10−63 GCKR
rs4148191 2 43896408 A −0.050 2.5 × 10−4 −0.054 1.1 × 10−6 3.7 × 10−09 ABCG5
rs6734238 2 113557501 A −0.047 4.8 × 10−13 0.023 1.2 × 10−5 5.8 × 10−17 IL1F10
rs4703642 5 74297918 A 0.018 3.0 × 10−3 −0.033 2.0 × 10−11 7.3 × 10−13 GCNT4
rs577272 6 31945942 A 0.020 1.1 × 10−3 0.026 2.3 × 10−7 1.6 × 10−8 SLC44A4
rs2858310 6 32776301 A 0.026 8.7 × 10−5 0.033 3.3 × 10−10 3.8 × 10−12 HLA-DQB1
rs3822857 6 116420624 C −0.032 2.7 × 10−6 −0.033 4.7 × 10−9 2.1 × 10−12 FRK
rs6951245 7 1024719 A 0.03 5.5 × 10−4 0.037 6.1 × 10−8 2.6 × 10−9 C7orf50
rs2126259 8 9222556 T −0.072 5.7 × 10−12 −0.085 9.0 × 10−24 1.4 × 10−31 PPP1R3B
rs11220463 11 125753421 A 0.032 2.8 × 10−3 −0.057 2.1 × 10−11 7.3 × 10−13 ST3GAL4
rs1183910 12 119905190 A −0.151 4.6 × 10−113 0.040 5.2 × 10−14 8.2 × 10−128 HNF1A
rs340025 15 58695599 T −0.036 8.3 × 10−9 0.015 2.4 × 10−3 2.5 × 10−10 RORA
rs1529711 19 10884434 T 0.030 8.4 × 10−4 0.038 6.3 × 10−7 3.4 × 10−8 CARM1
rs2228603 19 19190924 T 0.036 2.9 × 10−3 −0.118 4.3 × 10−34 1.1 × 10−35 NCAN
rs4420638 19 50114786 A 0.240 1.0 × 10−129 −0.184 5.2 × 10−111 3.8 × 10−249 APOC1
rs1800961 20 42475778 T −0.120 2.4 × 10−11 −0.118 5.7 × 10−13 1.0 × 10−20 HNF4A
Abbreviations: SNP single nucleotide polymorphism
For both CRP and the lipid phenotype, the effect estimates are according to the original GWAS
Chromosome and position are in NCBI genome build 36
Beta coefficient for total cholesterol represents 1-unit change in the standardized total cholesterol levels per copy increment in the coded allele
β coefficient for CRP represents 1-unit change in the natural log–transformed CRP (mg/L) per copy increment in the coded allele
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summary data instead of individual level data from all
participating cohorts. Thanks to close collaboration be-
tween studies across the world, researchers have per-
formed large GWAS meta-analyses for a vast amount of
phenotypes and this data is available for further research.
Second, we used the largest GWAS meta-analyses that
have so far been done on CRP and lipid levels to identify
pleiotropic genetic loci. By doing so, we enhanced the
statistical power to detect these loci considerably. Third,
we provided robust evidence for three novel CRP loci by
replication in an independent sample of genotyped indi-
viduals. A limitation of the bivariate meta-analysis is that
very strong signals in one of the individual traits may
overshadow the weak association with the other pheno-
type. We set a criterion for the univariate p-values <0.05
to minimize the chance of false positive findings. In
many instances the effect of the pleiotropic loci on CRP
or lipids is very small. We did not replicate all our pleio-
tropic loci. This could be due to lack of power in the
replication. In concordance, we replicated a larger pro-
portion of the lipid variants in the larger lipid replication
sample compared to CRP. Also, variants closer to signifi-
cance did replicate in the replication study of both CRP
and lipids. Also, several variants had substantial hetero-
geneity I2 in the replication which lowers the power for
replication. Furthermore, the replication sample size was
for some variants smaller than 17,743 due to absence of
the variants in one or more of the replication studies.
However, we cannot rule out the possibility that bivari-
ate p-values are driven by strong associations with one
of the phenotypes and produce false positive results. In
addition, for the replication of the lipid variants, we used
the Metabochip results from the GLGC. Several variants
selected for replication were not present on the Metabo-
chip. Although we selected the best available proxy SNP
for replication, variants in moderate LD may have lim-
ited power for replication. The method used in the
current manuscript to prioritize variants with pleiotropic
effects among inflammation and cholesterol are hypoth-
esis generating and further functional work regarding
the role of the identified variants in cholesterol metabol-
ism and inflammation is necessary.
Conclusions
Our results provide evidence for substantial overlap in
genetic susceptibility for chronic inflammation and lipid
metabolism. In addition, through bivariate genome-wide
association studies and replication in an independent
sample of individuals we could identify novel genes for
CRP.
Methods
The present study includes three stages. First, we per-
formed a bivariate GWAS combining published GWAS
data on CRP and lipids to identify pleiotropic variants
for CRP and lipids. In a second step, we sought replica-
tion of novel associations in independent samples of ge-
notyped individuals. Finally, we carried out functional
analyses in a third step to point out potential underlying
transcriptional mechanisms.
We used the data from the largest published GWAS
on CRP as well as the publically available GWAS on
lipids from GLGC to explore the genetic pleiotropy be-
tween inflammation and lipids [2, 3]. We combined
summary association test statistics from the CRP GWAS
separately with the GWAS on HDL-cholesterol, LDL-
cholesterol, triglycerides and total cholesterol. The CRP
GWAS meta-analysis included 65,000 individuals from
15 different studies in the discovery panel and after rep-
lication, 18 loci were genome-wide significantly associ-
ated with serum CRP level [3]. The lipids GWAS
comprised 100,184 individuals for total cholesterol,
95,454 for LDL-cholesterol, 99,900 for HDL-cholesterol
and 96,598 for triglycerides across 46 studies. The lipid
GWAS identified a total of 95 lipid loci (52 for total
cholesterol, 37 for LDL-cholesterol, 47 for HDL-
cholesterol and 32 for triglycerides) [2]. The CRP and
lipids GWAS used HapMap imputed data (build 36). All
studies that contributed genotype data to the CRP
GWAS also contributed data to the lipids GWAS. We
ensured that effect alleles were harmonized across the
two GWAS before applying the bivariate GWAS
method. Overall, 2,501,549 common Single Nucleotide
Polymorphisms (SNPs) were tested for their association
with CRP and total cholesterol, 2,501,711 with CRP and
triglycerides, 2,501,543 with CRP and HDL-cholesterol
and 2,501,749 with CRP and LDL-cholesterol. An aggre-
gated p-value was calculated using the method described
below.
Bivariate genome-wide association study
To better understand the shared biology of CRP and
lipids by further identifying shared genes between CRP
and lipids, we aimed to increase power by combining
the summary statistics from the CRP and lipid GWAS.
We chose to use a recently introduced method that per-
forms bivariate GWAS allowing for mixed directions of
effect. The method combines summary statistics (Z test
statistics) from univariate GWAS of CRP pairing with
the summary statistics of each univariate GWAS meta-
analysis of lipid phenotypes, using an empirical-weighted
linear-combined test statistics (eLC), implemented in a
C++ eLX package. We have recently used this method
in the identification of pleiotropic genes for menopause
and menarche and the details of the method are pre-
sented elsewhere. [8, 24]. eLC allows having opposite dir-
ection of effect on the combined phenotypes, which is
common between CRP and cholesterol phenotypes [2, 3].
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Briefly, eLC directly combines correlated Z test statistics
(calculated as β/SE derived from the original GWAS) ob-
tained from univariate GWAS meta-analyses with a
weighted sum of univariate test statistics to empirically
maximize the overall association signals and also to ac-
count for the phenotypical correlations among CRP and
lipids. Our eLC approach is expressed as
SeLC ¼
Xk
1
max Tkj j; cð Þ Tkj j½ 
where Tk is a matrix of K statistics for K phenotypes
(for bivariate, K is equal to 2) and c is a given non-
negative constant. The optimal weighting is estimated
empirically using the Monte Carlo Simulation [25] and
the bona-fide p-values for eLC test statistics are calcu-
lated through permutation. The sample covariance matrix
of the test statistics of all SNPs from the univariate GWAS
analyses is used as an approximation of the variance-
covariance matrix Σ of univariate test statistics. Σ:
Var Z1ð Þ Cov Z1; ;Z2ð Þ
Cov Z1; ;Z2ð Þ Var Z2ð Þ
 
where Z1 and Z2 consist of unbiased univariate test
statistics of all the SNPs for the two traits on genome-
wide scale for the first (Z1) and second (Z2) trait. The
null hypothesis in the bivariate analysis is β_1 = 0 AND
β_2 = 0; the H1 is β_1 not equal to 0 or β_2 not equal to
0. The results were considered genome-wide significant
when (1) the bivariate p-values were < 5 × 10−8 and (2)
the bivariate p-value was at least one order of magnitude
lower than both individual trait p-values and (3) when
the individual trait p-values were at least nominally
significant (p-value < 0.05). When multiple SNPs were
significant in a locus, the SNP with the lowest p-value
was chosen for replication. The eLC method is imple-
mented in eLX package using C++ (see Weblinks).
Replication study
The bivariate GWAS resulted in three possible scenarios.
First, the pleiotropic variant or the locus harboring the
pleiotropic variant (defined as ±500 MB of the pleio-
tropic SNP) was genome-wide significant in both the
primary univariate GWAS of CRP and the lipid trait.
Second, the pleiotropic signal was significant in either
the CRP or the lipid univariate GWAS. Third, the pleio-
tropic signal was neither genome-wide significant in the
CRP nor in the lipid GWAS. Per definition, a variant is
considered pleiotropic when there is robust evidence for
an association with two or more phenotypes. Therefore,
we only selected the variants that were not genome-wide
significant in the primary univariate GWAS for replica-
tion in an independent sample of genotyped samples.
We intended to replicate the novel associations with
CRP levels in three cohort studies that did not contrib-
ute to the original CRP GWAS. The independent co-
horts were the second (n = 1943) and third (n = 2962)
cohort of the Rotterdam Study and the LifeLines cohort
study (n = 12,838; Additional file 1) [6, 7, 26, 27]. The
total sample size for the replication of potentially novel
CRP variants comprised 17,743 individuals. In an at-
tempt to replicate the potential novel lipid variants, we
performed an in silico replication in the publicly avail-
able association results from the participants of the
GLGC that did not contribute to the original lipids
GWAS we used for the pleiotropy analysis. This replica-
tion set comprises 93,982 individuals genotyped using
the Metabochip array [13, 28]. For the SNPs that were
not available on the Metabochip, we selected the best
available proxy SNP on the Metabochip for replication
(r2 > 0.5). We used a Bonferroni corrected p-value of
0.05 divided by the number of SNPs tested for replica-
tion as a threshold of significance in the replication
study.
Ethics, consent and permissions
All participants of the Rotterdam and Lifelines study
provided written informed consent.
Expression Quantitative Trait Loci (eQTL)
In an attempt to annotate the pleiotropic variants to a
pleiotropic gene, we searched in tissues related to lipids
and inflammation for eQTL effects of the pleiotropic
variants or reasonable proxy variants (r2 > 0.80).
The eQTL analyses in whole blood comprised 5311 in-
dividuals from seven studies in the discovery setting with
both genetic and gene expression data available [9]. The
discovery meta-analysis including the seven studies
(EGCUT, InCHIANTI, Rotterdam Study, Fehrmann,
HVH, SHIP-TREND and DILGOM). Results are publicly
available (access URL: http://genenetwork.nl/bloodeqtl-
browser/). eQTLs were deemed cis when the distance
between the SNP and the midpoint of the RNA probe
was <250 kb. We only considered a significant eQTL ef-
fect of the pleiotropic SNP when the p-value exceeded
the FDR corrected threshold for multiple testing.
We searched for liver eQTL effects by use of the
eQTL browser provided by the university of Chicago
(access URL: http://eqtl.uchicago.edu/cgi-bin/gbrowse/
eqtl/). The liver tissue dataset by Schadt et al. comprised
427 individuals from European ancestry with liver spe-
cific gene expression and genotyping data available [10].
An eQTL was deemed cis when the SNP was within
1 Mb of the annotated start or stop site of the corre-
sponding structural gene. The authors used an FDR cor-
rection of 10 % for a significant association. The dataset
by Innocenti et al. comprised 266 individuals from 2 dif-
ferent studies. Cis eQTL was defined as <250 kb from
Ligthart et al. BMC Genomics  (2016) 17:443 Page 8 of 10
the gene transcription start site and the FDR for signifi-
cant association was set to 5 % [11].
We used the GTEx adipose tissue dataset (access URL:
http://www.gtexportal.org/home/eqtls/tissue?tissueNa-
me=Adipose_Subcutaneous) to search for potential
eQTLs in adipose tissue. The dataset consisted of 111
individuals with both gene expression and genotype data
available [12] Cis radius was defined as +/- 1mb from
transcription start site. A eQTL was deemed significant
when the FDR q-value < =5 %.
Additional file
Additional file 1: Study-specific Methods Section for the Replication
Section. Table S1. Replication Results for C-Reactive Protein. Table S2.
Replication Results for lipids. Table S3. Proxy variants for the Single
Nucleotide Polymophisms not Available on the Metabochip Array.
(DOCX 30 kb)
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CRP: C-reactive protein; GWAS: genome-wide association study.
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